ArticleEuropean heart journal. Cardiovascular Imaging2016
Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models.
Article in European heart journal. Cardiovascular Imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction.ESC heart failure · 2020Trial
- Stratifying risk of heart failure death and arrhythmic events: a ¹²³I-meta-iodobenzylguanidine-based multinomial logistic model.European journal of nuclear medicine and molecular imaging · 2026Article
- Multicenter development and validation of a probability-based model to diagnose Lewy body disease using ¹²³I-meta-iodobenzylguanidine.European journal of nuclear medicine and molecular imaging · 2026Article
- Effect of tofogliflozin on cardiac sympathetic nerve activity in type 2 diabetes mellitus patients with heart failure (TARGET-HF): rationale and design of the single-arm intervention trial.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Cardiac risk in recovered Covid-19 patients evaluated byScientific reports · 2025Article
- Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- CardiacPharmaceuticals (Basel, Switzerland) · 2022Review
- Usefulness of the 2-year iodine-123 metaiodobenzylguanidine-based risk model for post-discharge risk stratification of patients with acute decompensated heart failure.European journal of nuclear medicine and molecular imaging · 2022Article
- Machine learning-based risk model usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Paradoxical Prognostic Implications of Visceral Adiposity for Lethal Cardiac Events in Association with Impaired Cardiac Sympathetic Innervation in Chronic Heart Failure.Annals of nuclear cardiology · 2020Article
- How do we establish cardiac sympathetic nervous system imaging withJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Assessing arrhythmic risk withJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- A European myocardialJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure.European heart journal. Cardiovascular Imaging · 2018Article
- I-123 metaiodobenzylguanidine innervation imaging as a tool for norepinephrine transporter research: A possible application for genetic analysis in heart failure.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Influence of ROI definition on the heart-to-mediastinum ratio in planarJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- SPECT vs. PET in cardiac innervation imaging: clash of the titans.Clinical and translational imaging · 2018Review
- New horizons in cardiac innervation imaging: introduction of novelEuropean journal of nuclear medicine and molecular imaging · 2017Review
- Cross calibration ofAnnals of nuclear medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims(123)I meta-iodobenzylguanidine (MIBG) imaging has been extensively used for prognostication in patients with chronic heart failure (CHF). The purpose of this study was to create mortality risk charts for short-term (2 years) and long-term (5 years) prediction of cardiac mortality. METHODS AND
resultsUsing a pooled database of 1322 CHF patients, multivariate analysis, including (123)I-MIBG late heart-to-mediastinum ratio (HMR), left ventricular ejection fraction (LVEF), and clinical factors, was performed to determine optimal variables for the prediction of 2- and 5-year mortality risk using subsets of the patients (n = 1280 and 933, respectively). Multivariate logistic regression analysis was performed to create risk charts. Cardiac mortality was 10 and 22% for the sub-population of 2- and 5-year analyses. A four-parameter multivariate logistic regression model including age, New York Heart Association (NYHA) functional class, LVEF, and HMR was used. Annualized mortality rate was <1% in patients with NYHA Class I-II and HMR ≥ 2.0, irrespective of age and LVEF. In patients with NYHA Class III-IV, mortality rate was 4-6 times higher for HMR < 1.40 compared with HMR ≥ 2.0 in all LVEF classes. Among the subset of patients with b-type natriuretic peptide (BNP) results (n = 491 and 359 for 2- and 5-year models, respectively), the 5-year model showed incremental value of HMR in addition to BNP.
conclusionBoth 2- and 5-year risk prediction models with (123)I-MIBG HMR can be used to identify low-risk as well as high-risk patients, which can be effective for further risk stratification of CHF patients even when BNP is available.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.